ARTICLES BY MATHINI ILANCHERAN
-
NEW DOCUMENT4/15/2026
Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.
-
![Finance business trade economy-GettyImages-2230458034]( "U.S. Pharma Tariffs And MFN Become Law After April 2 Update")
U.S. Pharma Tariffs And MFN Become Law After April 2 Update4/15/2026Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.
-
![Target business strategy and success motivation symbol digital-GettyImages-2190546471]( "Careful Outsourcing Proves Key To Targeted Protein Degradation Drug Development")
Careful Outsourcing Proves Key To Targeted Protein Degradation Drug Development10/21/2025Discover how partnerships — especially with capable CROs — as well as resilient supply chains, digital enablement, regulatory foresight, and specialized talent impact the success of targeted protein degradation therapies.
-
![big pharma, private equity funds-GettyImages-2208792176]( "100% U.S. Drug Tariffs: Implications For Pharma And Outsourcing")
100% U.S. Drug Tariffs: Implications For Pharma And Outsourcing10/17/2025Research Manager Mathini Ilancheran explores the effects of U.S. drug tariffs on global supply chains, multinational pharma firms, and critical partners across drug development.
